GRN Carrier Resilience: Why Some Mutation Carriers Remain Asymptomatic

Overview

Target Knowledge Gap: FTD Gap #7: “Why do some carriers of pathogenic GRN mutations remain asymptomatic into old age?” (Score: 31/40) — Resilience factors could reveal protective mechanisms applicable to all FTD forms.

Disease: Frontotemporal Dementia (FTD) Priority Rank: 7 (Tier 1: Critical)

Rationale

Penetrance of GRN mutations is incomplete — not all carriers develop FTD. Some individuals carrying pathogenic GRN mutations remain asymptomatic into their 80s or 90s. Understanding what protects these “resilient” carriers could:

1. Reveal endogenous neuroprotective mechanisms applicable to all neurodegenerative diseases

2. Identify novel therapeutic targets

3. Guide timing of preventive interventions

4. Inform TMEM106B biology and lysosomal dysfunction pathways

Hypotheses

Resilience is multifactorial, likely involving:

1. Genetic modifiers: TMEM106B haplotypes, SORT1, and other rare variants

2. Compensatory progranulin expression: Alternative splicing or promoter usage — GRN has complex 5’ UTR regulation

3. Cellular stress resistance: Enhanced protein quality control, autophagy, lysosomal function

4. Cognitive reserve: Greater neural reserve or compensation — neurogenesis, synaptic plasticity

5. Immune modulation: Reduced neuroinflammation in resilient carriers — TREM2 variants may play a role

Experimental Design

Study Design

Case-control study comparing resilient GRN carriers vs affected carriers vs non-carrier controls

Cohort Definition

Group	Definition	N
Resilient carriers	GRN mutation carriers, age ≥70, asymptomatic	50
Affected carriers	GRN mutation carriers, FTD diagnosed	100
At-risk carriers	GRN mutation carriers, age <60, asymptomatic	50
Controls	Non-carriers, matched for age/education	100

Recruitment

• Source: ARTFL/LEFFTDS consortium, Genetic FTD Initiative (GENFI)

• Inclusion: Confirmed pathogenic GRN variant, comprehensive cognitive testing

Methods

Tier 1: Comprehensive phenotyping

Assessment	Purpose
Neurological exam	Document current status
Neuropsychological battery	Cognitive domain assessment
MRI with volumetry	Brain structure, hippocampal volume
CSF biomarkers	NfL, p-tau181, progranulin
PET imaging	FDG-PET for network dysfunction

Tier 2: Multi-omics profiling

1. Whole-genome sequencing:

   • Identify genetic modifiers (TMEM106B, other rare variants)

   • Polygenic risk score for FTD

2. RNA sequencing (blood):

   • Gene expression signatures

   • Immune cell activation patterns

3. Proteomics (CSF):

   • Protein abundance differences

   • Post-translational modifications

4. Epigenomics:

   • DNA methylation age

   • Epigenetic signatures of resilience

Tier 3: Mechanistic validation

1. iPSC-derived neurons (resilient vs affected carriers):

   • Compare neuronal survival under stress

   • Measure progranulin expression levels

   • Assess protein homeostasis capacity

2. Functional assays:

   • Autophagy flux measurement

   • Stress granule dynamics

   • Mitochondrial function

Expected Outcomes

Primary

1. Genetic modifier identification: Common and rare variants associated with resilience — TMEM106B, SORT1, GBA variants among targets

2. Biomarker panel for resilience: Blood/CSF signatures predicting resilience — NfL, p-tau181, progranulin levels, cytokine profiles

Secondary

1. Mechanistic pathway identification: How modifiers confer protection — lysosomal function, autophagy flux, protein homeostasis

2. Risk prediction model: Age at onset prediction for pre-symptomatic carriers — integrate with neuroimaging (MRI, FDG-PET) and CSF biomarkers

Mechanistic Linkages

This experiment connects to multiple neurodegenerative disease mechanisms:

• Lysosomal dysfunction: Progranulin is a lysosomal secretory protein; FTD with GRN mutations show lysosomal storage-like pathology

• Neuroinflammation: Progranulin modulates microglial activation via TREM2 and TLR signaling

• TDP-43 pathology: GRN mutations can lead to TDP-43 inclusions — overlapping with ALS

• Epigenetics: DNA methylation age and epigenetic signatures — GRN expression is epigenetically regulated

• Stress granules: Progranulin deficiency leads to stress granule accumulation and RNA granule dysfunction

Feasibility Assessment

Dimension	Score	Rationale
Technical Feasibility	9/10	Existing cohorts, standard techniques
Timeline	24 months	12 mo recruitment, 12 mo analysis
Cost	$2M	Cohort assessments (800K), omics (800K), iPSC ($400K)
Data Availability	8/10	ARTFL, GENFI already have carrier data

Risk Assessment

Risk	Likelihood	Mitigation
Insufficient resilient carriers	Medium	Expand international collaboration
Survivor bias (only oldest carriers identified)	High	Also study carriers at different ages
Variable mutation types	Medium	Stratify by mutation type in analysis

Comparison to Existing Research

• GENFI: Primarily focused on affected carriers; this focuses on resilient

• TMEM106B studies: One known modifier; more likely exist

• AD resilience studies: Methodological framework adaptable to FTD

Research Team Requirements

Role	Institution	Expertise
Lead PI	Mayo Clinic (Boeve)	GRN natural history
Genetics	UCSF (Boxer)	FTD genetics
Biostatistics	UPenn (Drayman)	Resilience modeling
iPSC	Cambridge (Isaacs)	FTD iPSC models

Therapeutic Implications

1. Target identification: Pathways that confer resilience → drug targets

2. Biomarker development: Predict which carriers will remain asymptomatic

3. Timing guidance: When to intervene in pre-symptomatic carriers